Solutions for Reprogramming of Glycolytic Metabolism in the TME
Relying on the technology platform of the tumor microenvironment center, Alfa Cytology is committed to providing global collaborators with a full range of solutions and services to study the molecular mechanisms of glycolytic reprogramming in the tumor microenvironment (TME) to help you successfully achieve your research goals.
Introduction
In addition to the characteristics of tumor cells, tumor progression and metastasis also depend on the reprogramming of tumor cell glucose metabolism by the tumor microenvironment (TME). The reprogramming of tumor cell glucose metabolism means that tumor cells prefer to undergo glycolysis in the cytoplasm in the presence of oxygen, known as the "Warburg effect" or "aerobic glycolysis". Tumor microenvironment components such as tumor-associated fibroblasts, macrophages, and immune cells can also undergo glycolytic reprogramming, mainly manifested as enhanced glycolysis, increased glucose uptake and consumption, enhanced lipid and protein synthesis, and increased amino acid uptake and catabolism such as glutamine, etc. These metabolic changes will facilitate tumor malignant proliferation and adaptation to unfavorable survival environment.
Solutions
Abnormal tumor glucose metabolism is an important component of metabolic reprogramming in cancer. Since glycolytic reprogramming is a key downstream metabolic pathway in which various oncogenic signals act together. Therefore, targeting glycolytic metabolism in cancer cells can curb malignant tumor progression driven by various oncogenic signals. Currently, a series of glycolytic inhibitors, including 2-deoxyglucose, AZD-3965 and CPI-613, have been applied in clinical trials for oncology treatment. The results of clinical trials obtained have confirmed that glucose metabolism inhibitors can significantly enhance the efficacy of chemotherapy/radiotherapy.
Alfa Cytology has established an innovative technology platform for tumor microenvironment centers and is developing multiple technologies to provide high quality solutions and services to our global collaborators. Designing scientifically rational experiments to deeply investigate the influence and role of tumor microenvironment (TME) on tumor glycolytic reprogramming, revealing the biological functions of abnormal glycolytic pathways in the tumor microenvironment (TME), and confirming the in vivo anticancer effects of inhibiting this metabolic pathway in the corresponding animal models, we expect to identify new targets and develop new antitumor therapeutic approaches.
Key technologies
Metabolomics technologies will monitor metabolite changes or fluctuations during metabolic reprogramming in specific tumor microenvironments to predict tumor progression, or monitor the response of the tumor microenvironment to metabolic reprogramming interventions to obtain altered metabolic profiles, assess the molecular etiology of established tumors, identify metabolite changes in biological effects, and assist in studying the mechanisms of tumor metabolic reprogramming. Alfa Cytology provides services related to this biological problem such as target metabolite analysis, metabolite fingerprinting, metabolic profiling and and metabolite characterization and quantification.
Combined multi-omics analysis can obtain panoramic information on gene transcription, protein and metabolic levels in the tumor microenvironment to understand the function of biological systems at a higher level.
As one of the world's leading companies in the field of tumor microenvironment (TME) research, Alfa Cytology is committed to supporting researchers in making groundbreaking scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. With years of experience in the field of TME, we are ready to provide reliable solutions and quality services to our customers. If you have any special needs or questions, please feel free to contact us for support from our experienced experts.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.